This document summarizes information about the antibiotic drug Ceftazidime-Avibactam. It notes that both Ceftazidime and Avibactam are mainly excreted by the kidneys. Ceftazidime-Avibactam has activity against many Gram-negative bacteria, including ESBL-producing Enterobacteriaceae and some Pseudomonas aeruginosa. However, it has no activity against Acinetobacter baumannii. The combination extends the activity of Ceftazidime to include organisms producing various beta-lactamases. Potential side effects include hypersensitivity reactions, Clostridium difficile infection, and seizures in patients with renal impairment. Dosing adjustments are recommended

1. Ceftazidime Avibactm

2. Ceftazidime avibactum
Excretion
● Both Ceftazidime and Avibactam are excreted mainly by the kidneys.
● Approximately 80% to 90% of an intravenous dose of ceftazidime is excreted unchanged by
the kidneys over a 24-hour period.
● Ceftazidime is eliminated almost solely by the kidneys; its serum half-life is significantly
prolonged in patients with impaired renal function.
● Renal Half-life: 3.27 hours (Ceftazidime), 2.22 hours (Avibactam).
Spectrum of activity:
● Citrobacter freundii complex
● Enterobacter cloacae
● Escherichia coli
● Klebsiella oxytoca
● Klebsiella pneumoniae
● Proteus mirabilis
● Pseudomonas aeruginosa
● Haemophilus influenzae
● Serratia marcescens
● Citrobacter koseri
● Enterobacter aerogenes
● Morganella morganii
● Providencia rettgeri
● Providencia stuartii
No Activity Against A. Baumannii
Ref: Package Insert - Avycaz

3. Ceftazidime avibactum
● Ceftazidime-avibactam combines the anti-pseudomonal cephalosporin ceftazidime, and the novel
non-β-lactam β-lactamase inhibitor avibactam, which extends the in vitro activity of ceftazidime to
include Gram-negative organisms producing Ambler class A (eg, ESBLs, Klebsiella pneumoniae
carbapenemase), class C (AmpC) and some class D (OXA-48) β-lactamases.
● This microbiological profile covers most carbapenem-non-susceptible Enterobacteriaceae and
multidrug resistant (MDR) P. aeruginosa (excluding metallo-β lactamase producers), and makes
the combination a potential alternative to carbapenems for the treatment of serious Gram-
negative infections, including those caused by some carbapenemase-producing bacteria.
Side effects:
● Hypersensitivity reactions: Includes anaphylaxis and serious skin reactions. Cross-hypersensitivity
may occur in patients with a history of penicillin allergy. If an allergic reaction occurs, discontinue
AVYCAZ. (5.2)
● Clostridium difficile-associated diarrhea (CDAD): CDAD has been reported with nearly all systemic
antibacterial agents, including AVYCAZ. Evaluate if diarrhea occurs. (5.3)
● Central Nervous System Reactions: Seizures and other neurologic events may occur, especially in
patients with renal impairment. Adjust dose in patients with renal impairment.
Ref: Package Insert - Avycaz

4. Ceftazidime avibactum
Dosage
For adult patients with Renal Impairment:
Ref: Package Insert - Avycaz

5. Thanks !